Restart Life Sciences Corp. (HEAL.CN)
Restart Life Sciences Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.07, down 6.67% on the session, giving a market capitalisation of $2.6M. Its beta of -0.78 implies it has historically moved less than the broad market.
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Restart Life Sciences Corp. is most often compared with the following Healthcare names: